Naloxone Market Share Is Estimated to Grow at a CAGR of 11.4% By 2026 | Future Growth Analysis, Emerging Trends and Global Industry Insights

SEATTLE, April 01, 2021, (PHARMIWEB) — Naloxone Market- Insights

Naloxone is an opioid antagonist used for the treatment of opioid overdose such as of morphine and heroine. In the U.S., the federal agency Food and Drug Administration (FDA) lists naloxone under prescription drugs. However, in several other countries such as Italy and Australia, naloxone can be bought over-the-counter (OTC). Naloxone is available in various strengths of 0.4 mg/ml, 1mg/ml, 0.4mg/0.4ml, 4mg/0.1ml, and others. The drug can be administrated using various routes such as intranasal, intramuscular/subcutaneous, and intravenous. The recently launched intranasal naloxone products can be administrated by anyone (non-medical professional). However, only medical professionals are allowed to administrate intravenous products of naloxone.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1804

Increasing approval and launch of novel naloxone products is expected to boost the global naloxone market growth

Key players in the market are focused on approval and launch of novel naloxone products, which is expected boost growth of the market over the forecast period. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) approved Adapt Pharma Inc.’s NARCAN Nasal Spray 2 mg formulation for emergency treatment of known or suspected opioid overdose. In 2016, Mylan N.V. launched its naloxone hydrochloride injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. It is therapeutically equivalent to the naloxone hydrochloride injection 0.4 mg/mL, of Hospira Inc. In September 2017, Mundipharma International Limited received approval from European Medicines Agency (EMA) for its product (intranasal naloxone 1.8 mg) to use in emergency reversal of opioid overdose.

The global naloxone market size was valued at US$ 310.2 Mn in 2017 and is expected to witness a CAGR of 11.4% over the forecast period (2018 – 2026).

Figure 1. Global Naloxone Market Share (%), By Strength, 2018–2026

Source: Coherent Market Insights Analysis (2018)

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3mcK5Op

Increasing drug abuse in key regions is expected to boost demand for naloxone

Increasing number of opioid overdose cases is expected to lead to high demand for naloxone products, thereby aiding in growth of the global naloxone market. For instance, according to the data published by the U.S. Department of Health and Human Services (HHS) in 2016, around 11.5 million people misuse prescription drugs and around 948,000 people use heroin. According to the data published by National Institute on Drug Abuse, 2018, in the U.S., everyday over 115 people die due to opioid overdosing. According to same source, in the U.S. opioid overdose increased by 30% from July 2016 through September 2017 in 52 areas in 45 states.

Figure 2. Global Naloxone Market Share (%), By Region, 2026

Source: Coherent Market Insights Analysis (2018)

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/naloxone-market-to-surpass-us-8848-mn-threshold-by-2026-1098

Favorable reimbursement scenarios for naloxone products is also expected to contribute to the market growth

Favorable reimbursement scenario in major countries in North America and Europe is expected to increase adoption of naloxone. Currently, several insurances cover and reimburse for naloxone administered directly in a medical setting.

Moreover, in the U.S., increasing number of states have started covering take-home naloxone, which is further expected to increase adoption of take-home naloxone. For instance, from January 2014, New York State Medicaid program began to cover the intramuscular formulation of take-home naloxone.

The market in North America is expected to hold dominant position over the forecast period. This is owing to presence of novel naloxone products such as Narcan nasal spray and EVZIO (naloxone hydrochloride injection), which is still not present in any other region. Moreover, increasing company and organization initiatives to increase access of naloxone is also expected to contribute to the market growth. For instance, in February 2018, Loyola Medicine collaborated with the Cook County Department of Homeland Security and Emergency Management to train police officials to use Narcan in case of opioids overdose. In 2016, Adapt Pharma Limited partnered with Smith Medical Partners, LLC for distribution of free Narcan (Naloxone HCl) nasal spray in all high schools in the U.S.

Increasing approval and launch of novel naloxone products is expected to boost the market growth in Europe over the forecast period. For instance, in July 2017, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from French Regulatory Agency ANSM for its new Nalscue naloxone hydrochloride nasal spray indicated for emergency treatment of characterized or suspected opioid overdose in France. In February 2017, Adapt Pharma Limited filed marketing application for its product Naloxone Hydrochloride (HCl) nasal spray in Europe.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1804

Regulatory Scenario

In 2016, Therapeutic Goods Administration (TGA) placed naloxone on Schedule 3 when used for the treatment of opioid overdose, thus allowing the over-the-counter (OTC) purchase of naloxone in Australia.

In Europe, several countries allow take-home naloxone due to high rate of opioid overdose in this region. Denmark, Estonia, Germany, Italy, Norway, Spain, and the U.K. (EMCDDA, 2015c) support take-home naloxone programs.

According to the data published by Regulatory Affairs Professional Society, naloxone is still not approved by the U.S. FDA as an over-the-counter (OTC) drug. However, some organizations such as Walgreens pharmacies are providing naloxone products over-the-counter in over 5,800 of its 8,200 stores to increase the access of naloxone.

Key players operating in the naloxone market include, Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

Table of Content

Global Naloxone Market Research Report
Section 1: Global Naloxone Industry Overview
Section 2: Global Economic Impact on Naloxone Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Naloxone Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Naloxone Market Forecast

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737